-
公开(公告)号：US20090326044A1
公开(公告)日：2009-12-31
申请号：US12536698
申请日：2009-08-06
IPC分类号： A61K31/7105
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K—2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
公开(公告)号：US07592324B2
公开(公告)日：2009-09-22
申请号：US11345361
申请日：2006-02-01
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者的眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
3.发明申请RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS 审中-公开RNAi介导的抑制肿瘤坏死因子ALPHA相关病症公开(公告)号：US20100166676A1
公开(公告)日：2010-07-01
申请号：US12700188
申请日：2010-02-04
IPC分类号： A61K9/12 , A61K31/7088 , A61K31/7125
CPC分类号： C12N15/1138 , A61K31/7088 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/346 , C12N2310/351 , C12N2320/30
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有TNFα相关病症或具有发展TNFα相关病症如眼病干眼症，过敏性结膜炎或眼部炎症或诸如皮炎，鼻炎的患者的患者 ，或哮喘。
-
4.发明申请公开(公告)号：US20110124708A1
公开(公告)日：2011-05-26
申请号：US12967121
申请日：2010-12-14
IPC分类号： A61K31/713 , A61P27/02 , A61P9/12
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; 1和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
公开(公告)号：US20120115870A1
公开(公告)日：2012-05-10
申请号：US13348376
申请日：2012-01-11
申请人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shepard , Mark R. Hellberg , Peter G. Klimko , Abbot F. Clark
发明人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shepard , Mark R. Hellberg , Peter G. Klimko , Abbot F. Clark
IPC分类号： A61K31/5377 , C07D401/14 , A61K31/4439 , A61K31/437 , C07D471/04 , A61P27/02 , A61K31/506 , A61P27/06 , A61K31/519 , C07D417/12 , A61K31/495 , C07D413/12 , C07D413/14 , C12Q1/02 , C07D405/14
CPC分类号： G01N33/5008 , A61K31/357 , A61K31/381 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K45/06 , G01N33/5023 , G01N33/5044 , A61K2300/00
摘要： An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
摘要翻译： 公开了一种可用于治疗青光眼和控制眼内压的眼用药物组合物，其包含有效量的ALK5受体活性的选择性调节剂。 还公开了一种治疗青光眼并控制眼内压的方法，其包括将治疗有效量的包含ALK5受体活性的选择性调节剂的药物组合物施用于患者的受影响的眼睛。
-
6.发明申请ANTAGONISTS OF CI-M6P/IGF2R FOR PREVENTION AND TREATMENT OF CTGF-MEDIATED OCULAR DISORDERS 审中-公开CI-M6P / IGF2R预防和治疗CTGF介导性眼病的拮抗剂公开(公告)号：US20100247548A1
公开(公告)日：2010-09-30
申请号：US12796748
申请日：2010-06-09
IPC分类号： A61K39/395 , A61K38/00 , A61K31/70 , A61K31/7088 , A61K31/175 , A61P27/02
CPC分类号： A61K31/7088 , A61K31/70 , A61K38/00
摘要： Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.
摘要翻译： 提供阳离子非依赖性甘露糖-6-磷酸/胰岛素样生长因子-II受体的拮抗剂用于在受体信号下调的方法中降低CTGF信号传导，并且下游减少涉及不适当CTGF的眼部疾病中结缔组织生长因子的信号转导 信令。 涉及不适当CTGF信号的眼部疾病包括例如高眼压症，青光眼，青光眼性视网膜病变，视神经病变，黄斑变性，糖尿病性视网膜病变，脉络膜新生血管形成和增殖性玻璃体视网膜病变。 通过施用本发明的拮抗剂治疗此类病症。
-
7.发明申请PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开PAI-1表达和活化抑制剂治疗眼病公开(公告)号：US20110105574A1
公开(公告)日：2011-05-05
申请号：US13006984
申请日：2011-01-14
IPC分类号： A61K31/41 , A61K31/403 , A61P27/02
CPC分类号： A61K31/404 , A61K31/19 , A61K31/192 , A61K31/22 , A61K31/277 , A61K31/353 , A61K31/366 , A61K31/403 , A61K31/41 , A61K31/416 , A61K31/437 , A61K31/4436 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K38/16
摘要： The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.
摘要翻译： 本发明在一个实施方案中涉及用于治疗患者青光眼或升高的IOP的方法，包括向患者施用有效量的包含抑制PAI-1表达或PAI-1活性的药物的组合物。 本发明的另一个实施方案是治疗需要的受试者中PAI-1相关的眼部疾病的方法，包括向患者施用有效量的包含抑制PAI-1活性或表达的药物的组合物。
-
公开(公告)号：US20100035969A1
公开(公告)日：2010-02-11
申请号：US12577267
申请日：2009-10-12
申请人： Allan R. Shepard , Iok-Hou Pang
发明人： Allan R. Shepard , Iok-Hou Pang
IPC分类号： A61K31/7105 , A61P27/02
CPC分类号： C12N15/1136 , A61K31/713 , C12N15/111 , C12N2310/14 , C12N2320/32
摘要： RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制涉及CTGF表达的眼部疾病中的结缔组织生长因子mRNA表达。 涉及异常CTGF表达的眼部疾病包括青光眼，黄斑变性，糖尿病性视网膜病变，脉络膜新生血管形成，增生性玻璃体视网膜病变和伤口愈合。 通过施用本发明的干扰RNA来治疗这些病症。
-
9.发明申请PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA 审中-公开用于高血压控制和GLAUCOMA治疗的PRENYLTRANSFERASE抑制剂公开(公告)号：US20120108632A1
公开(公告)日：2012-05-03
申请号：US13344258
申请日：2012-01-05
申请人： Allan R. Shepard , Debra L. Fleenor
发明人： Allan R. Shepard , Debra L. Fleenor
IPC分类号： A61K31/4709 , A61K31/216 , C07D233/64 , A61P27/02 , C07C229/66 , A61K31/205 , A61K31/417
CPC分类号： A61K31/166 , A61K31/195 , A61K31/24 , A61K31/417 , A61K31/4172 , A61K31/4178 , A61K31/4709 , A61K31/557
摘要： The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor.
摘要翻译： 本发明在一个实施方案中涉及治疗青光眼或升高的眼内压的方法，其包括施用药学有效量的包含至少一种异戊烯基转移酶抑制剂的组合物。 在另一个实施方案中，本发明涉及用于治疗眼内压升高和青光眼的组合物，其包含药学有效量的异戊烯基转移酶抑制剂。
-
10.发明申请ANTAGONISTS OF ENDOTHELIAL DIFFERENTIATION GENE SUBFAMILY 3 (EDG-3, S1P3) RECEPTORS FOR PREVENTION AND TREATMENT OF OCULAR DISORDERS 审中-公开内分泌基因亚型3（EDG-3，S1P3）受体，用于预防和治疗眼部疾病的拮抗剂公开(公告)号：US20100183629A1
公开(公告)日：2010-07-22
申请号：US12749331
申请日：2010-03-29
申请人： Debra L. Fleenor , Allan R. Shepard , Iok-Hou Pang
发明人： Debra L. Fleenor , Allan R. Shepard , Iok-Hou Pang
IPC分类号： A61K39/395 , A61K38/02 , A61K31/426 , A61K31/54 , A61K31/661 , A61K31/167 , A61K31/17 , A61P9/12 , A61P27/02 , A61P27/06
CPC分类号： A61K31/17 , A61K31/426 , A61K31/54
摘要： Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
摘要翻译： 提供了S1P3（Edg-3）受体的拮抗剂，用于在受体信号下调的方法中减弱Smad信号，并且下游减少涉及CTGF积聚的眼部疾病中结缔组织生长因子的产生。 涉及不适当的CTGF积聚的眼部疾病包括例如眼高压，青光眼，青光眼性视网膜病变，视神经病变，黄斑变性，糖尿病性视网膜病变，脉络膜新生血管形成，增生性玻璃体视网膜病变和眼部伤口愈合。 通过施用本发明的拮抗剂治疗此类病症。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.023 秒)